Pfizer Looks Back at 2024 in the Annual Review

Last year, Pfizer celebrated our 175th anniversary. As proud as we are of our nearly two centuries of work, we know that reaching such a milestone is only possible because we don’t take a single year—or single day—for granted.

That means both celebrating our accomplishments and relentlessly improving. Today, we’re sharing our Annual Review, which outlines how we did just that in 2024.

The good news is that 2024 was a successful year for Pfizer; the great news is that 2025 is yet another opportunity to outdo yesterday. The results compiled inside our Annual Review detail the ways we excelled over the past year and how our work positions us for the future.

As with our previous Annual Review, the report is comprised entirely of a letter from our CEO Albert Bourla. He begins by sharing that we achieved or exceeded our goals around each of the five strategic priorities put in place for 2024:

• Achieve world-class Oncology leadership
• Deliver the next wave of pipeline innovation
• Maximize performance of our new products
• Expand margins by realigning our cost base
• Allocate capital to enhance shareholder value

“2024 was a special year for Pfizer, our 175th anniversary as a company. That’s 175 years of groundbreaking innovation and positive impact for millions of patients around the world. As proud as we are of what we’ve achieved, we’re even more excited about our future. We believe we have a clear strategy, scientific leadership and strong capabilities that position us to create sustained, long-term value for shareholders and positive impact for the people who place their trust in us for their health,” Bourla writes.

The letter then goes on to highlight Pfizer’s financial performance in 2024 before delving into the accomplishments from the past year, including strides we’ve made in our work to expand patient access to medicines, our fight against cancer, the increasing incorporation of Artificial Intelligence into our processes, and more.

As Albert writes, Pfizer’s strong 2024 positions us well for the future, with the strategy, leadership, and capabilities in place to help us reach our 200th anniversary.

Read on to learn more about Pfizer’s 2024 in our 2024 Annual Review (Pfizer.com/Annual)